| This article has been cited by |
| 1 | | |
| Pablo Duarte,Antonio Cuadrado,Rafael León |
| .2020;264()229 |
| [DOI] |
|
| 2 | Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect? | |
| Felix-Martin Werner,Rafael Coveñas |
| Epilepsy & Behavior.2017;71()124 |
| [DOI] |
|
| 3 | An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy | |
| Arne Reimers,Hanna Ljung |
| Expert Opinion on Pharmacotherapy.2019;20(8)909 |
| [DOI] |
|
| 4 | Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease | |
| Haruo Nishijima,Yasuo Miki,Shinya Ueno,Masahiko Tomiyama |
| Parkinson's Disease.2018;2018(8)1 |
| [DOI] |
|
| 5 | Drugs related to monoamine oxidase activity | |
| Zdenek Fišar |
| Progress in Neuro-Psychopharmacology and Biological Psychiatry.2016;69(8)112 |
| [DOI] |
|
| 6 | Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study | |
| Tatsuhiro Terada,Masamichi Yokokura,Etsuji Yoshikawa,Masami Futatsubashi,Satoshi Kono,Takashi Konishi,Hiroaki Miyajima,Takanori Hashizume,Yasuomi Ouchi |
| Annals of Nuclear Medicine.2016;30(8)579 |
| [DOI] |
|
| 7 | Zonisamide for the Treatment of Parkinson Disease: A Current Update | |
| Chengqian Li,Li Xue,Yumei Liu,Zhengjie Yang,Song Chi,Anmu Xie |
| Frontiers in Neuroscience.2020;14(8)579 |
| [DOI] |
|
| 8 | The agony of the agonists: a review of impulsivity and withdrawal syndromes in Parkinson's disease treatment | |
| Andrea J Lindahl,Douglas G MacMahon |
| Future Neurology.2015;10(4)357 |
| [DOI] |
|
| 9 | Ion-Channel Antiepileptic Drugs: An Analytical Perspective on the Therapeutic Drug Monitoring (TDM) of Ezogabine, Lacosamide, and Zonisamide | |
| Roberto Mandrioli,Michele Protti,Lorenzo Marincich,Laura Mercolini |
| Analytica.2021;2(4)171 |
| [DOI] |
|
| 10 | Ion-Channel Antiepileptic Drugs: An Analytical Perspective on the Therapeutic Drug Monitoring (TDM) of Ezogabine, Lacosamide, and Zonisamide | |
| Yoshikuni Mizuno |
| Analytica.2022;2(4)2823 |
| [DOI] |
|
| 11 | The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials | |
| Marie Selvy,Mélissa Cuménal,Nicolas Kerckhove,Christine Courteix,Jérôme Busserolles,David Balayssac |
| Expert Opinion on Drug Safety.2020;19(6)707 |
| [DOI] |
|
| 12 | The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6 | |
| Muhammad M. Hossain,Blair Weig,Kenneth Reuhl,Marla Gearing,Long-Jun Wu,Jason R. Richardson |
| Experimental Neurology.2018;308(6)111 |
| [DOI] |
|
| 13 | Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs | |
| D. Caccamo,L. R. Pisani,P. Mazzocchetti,R. Ientile,P. Calabresi,F. Pisani,C. Costa |
| Neurochemical Research.2016;41(1-2)340 |
| [DOI] |
|
| 14 | Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs | |
| F.-M. Werner,R. Coveñas |
| Neurochemical Research.2017;41(1-2)340 |
| [DOI] |
|
| 15 | Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs | |
| Yoshikuni Mizuno |
| Neurochemical Research.2020;41(1-2)1 |
| [DOI] |
|
| 16 | Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs | |
| Josef Finsterer |
| Neurochemical Research.2016;240(1-2)473 |
| [DOI] |
|
| 17 | Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity | |
| Maiko T. Uemura,Takeshi Asano,Rie Hikawa,Hodaka Yamakado,Ryosuke Takahashi |
| Neuroscience Research.2017;124(1-2)25 |
| [DOI] |
|
| 18 | Rational drug discovery design approaches for treating Parkinson’s disease | |
| Cornelis J Van der Schyf |
| Expert Opinion on Drug Discovery.2015;10(7)713 |
| [DOI] |
|
